Lenoir, NC November 2, 2020 – Exela is pleased to announce that it has divested its ownership of the NDA 212535, covering L-Cysteine Hydrochloride Injection. This NDA was acquired from Avadel Legacy Pharmaceuticals as part of a four products transaction which closed on July 1, 2020. The divestiture includes a license that allows the new owner to enter the market well before the expiry of Exela’s several patents, after obtaining any necessary approvals. “We are pleased to have completed this transaction quickly and efficiently with a competent and reputable injectable products manufacturer/marketer that will commercialize the L-Cysteine Injection product,” stated Dr.
Read More